Cargando…
Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
Anti-programed cell death-1 (Anti-PD-1) is a promising immunotherapy for advanced cancers. Autoimmune pneumonitis is a rare but potentially serious toxicity induced by anti-PD-1 immunotherapy. We report a case of therapy-induced pneumonitis in the setting of combined nivolumab, anti-PD-1 immunothera...
Autores principales: | Yu, Nathan Y, Deftos, Michael, Wang, Clifford C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388854/ https://www.ncbi.nlm.nih.gov/pubmed/30820369 http://dx.doi.org/10.7759/cureus.3748 |
Ejemplares similares
-
Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023) -
Acute Hypersensitivity Pneumonitis Associated With a High Ki-67 Proliferative Index
por: Nabrinsky, Edward, et al.
Publicado: (2020) -
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report
por: Fan, Frank S, et al.
Publicado: (2019) -
Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India
por: Anthony, Michael L, et al.
Publicado: (2022) -
Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum
por: Laishram, Devina, et al.
Publicado: (2021)